Area:
Neuroscience, addiction
We are testing a new system for linking grants to scientists.
The funding information displayed below comes from the
NIH Research Portfolio Online Reporting Tools and the
NSF Award Database.
The grant data on this page is limited to grants awarded in the United States and is thus partial. It can nonetheless be used to understand how funding patterns influence mentorship networks and vice-versa, which has deep implications on how research is done.
You can help! If you notice any innacuracies, please
sign in and mark grants as correct or incorrect matches.
Sign in to see low-probability grants and correct any errors in linkage between grants and researchers.
High-probability grants
According to our matching algorithm, Sandra L. Haberny is the likely recipient of the following grants.
Years |
Recipients |
Code |
Title / Keywords |
Matching score |
2003 — 2004 |
Haberny, Sandra L |
F31Activity Code Description: To provide predoctoral individuals with supervised research training in specified health and health-related areas leading toward the research degree (e.g., Ph.D.). |
Erk Signaling in Food-Restricted, Drug-Sensitive Rats @ New York University School of Medicine
DESCRIPTION (provided by applicant): Behavioral studies indicate that chronic food restriction enhances sensitivity to the rewarding and motor-activating effects of abused drugs. We and others have demonstrated a role for the D1 dopamine receptor (D1R) subtype among the several localized neuroadaptations that correlate with this increased sensitivity. Related evidence indicates that D1R-mediated activation of MAP kinase signaling may be a factor in the enhanced responses of drug-sensitive rats. Our objective is to determine whether there is a brain regional increase in MAP kinase signaling upon D1R activation in chronically food-restricted (FR) compared to ad libitum-fed (AL) rats. The first aim is to determine, by Western Blot and immunohistochemistry (IHC), if intracerebroventricular injection of a D1 agonist, SKF-82958, results in increased ERK1/2/MAP kinase phosphorylation in striatal regions of FR versus AL rats. The second aim is to determine by IHC whether a MAP/ERK kinase (MEK) inhibitor, PD98059, reverses the augmented SKF-82958-induced c-Fos expression otherwise seen in the striatum of FR versus AL rats. The third aim is to determine, by measuring photobeam interruption to count movements, whether PD98059 reverses the augmented SKF-82958-induced locomotor activity that is otherwise observed in FR compared to AL rats.
|
1 |